Wednesday, October 29, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Antibody-drug conjugate highly effective in preventing recurrence in patients with early stage HER2+ breast cancer, trial finds

June 27, 2024
in Cancer
Reading Time: 3 mins read
0
Antibody-drug conjugate highly effective in preventing recurrence in patients with early stage HER2+ breast cancer, trial finds
67
SHARES
608
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.

A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.

In a clinical trial involving 512 patients with the earliest stage of breast cancer that tested positive for the HER2 protein, 97% of those treated with trastuzumab emtansine (T-DM1) after surgery were alive and free of invasive cancer five years after treatment. The results, published online today in the Journal of Clinical Oncology, suggest that T-DM1 is a reasonable treatment approach for this stage 1 population, the study authors say.

In conjunction with the trial, researchers looked for biomarkers of whether the cancer was likely to recur even after treatment with T-DM1. They found that patients with high scores on the HER2DX test – which weighs clinical factors and the activity of four genes within tumor tissue – had a greater risk of recurrence.

“Patients with stage 1 HER2-positive breast cancer have recurrence rates of 5 to 30%. Post-surgical treatment with chemotherapy and the antibody trastuzumab, which binds to HER2, can significantly reduce the risk of recurrence in these patients. But the side effects can have a detrimental impact on patients’ quality of life,” says study lead author Paolo Tarantino, MD, of Dana-Farber and the University of Milan (Italy). “In this study, we evaluated T-DM1, which links trastuzumab to a powerful chemotherapy agent, for effectiveness and toxicity in this group of patients.”

T-DM1, known as an antibody-drug conjugate, is currently approved for post-surgical, or adjuvant, treatment of patients with HER2-positive breast cancer which remains after pre-surgical treatment, and is also approved for patients with metastatic HER2-positive breast cancer. The new study, a randomized phase II trial dubbed ATEMPT, involved patients with a stage 1 HER2-positive cancer, meaning it was small and without lymph node involvement.

The trial enrolled 512 patients at cancer centers across the U.S.: 384 of the participants were treated with T-DM1 and 128 were treated with chemotherapy and trastuzumab. Investigators found that, five years after treatment, 97% of patients receiving T-DM1 had no evidence of cancer recurrence. The rate of clinically relevant toxicities was similar in the T-DM1 group and the chemotherapy-and-trastuzumab group. However, patient-reported outcomes from this study shower better quality of life with T-DM1, that was associated with less neuropathy, less hair loss and better work productivity than chemotherapy and trastuzumab.

Results of HER2DX testing showed that patients whose risk score was above an established threshold had a significantly higher chance of a cancer recurrence.

“The ATEMPT trial has taught us that one year of T-DM1 after surgery for patients with a stage 1 HER2-positive cancer leads to outstanding long term outcomes, making it a reasonable treatment approach for select patients,” says senior author Sara Tolaney, MD, MPH, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute.

The trial was supported by Genentech, Gloria Spivak Faculty Advancement Fund, and Susan G. Komen.



Journal

Journal of Clinical Oncology

Article Publication Date

27-Jun-2024

Share27Tweet17
Previous Post

Experts develop strategies for successful care of older adults with obesity

Next Post

June research news from the Ecological Society of America

Related Posts

blank
Cancer

Static Magnetic Fields Boost Doxorubicin’s Leukemia Attack

October 29, 2025
blank
Cancer

STXBP6 Controls Ovarian Cancer via PI3K/AKT Pathway

October 29, 2025
blank
Cancer

Allison Institute’s Third Annual Scientific Symposium Features Panel Discussion with Five Nobel Laureates

October 28, 2025
blank
Cancer

Breakthrough in Glioblastoma Treatment: Implantable “CANDI” Wafer Demonstrates Potential to Prevent Tumor Recurrence

October 28, 2025
blank
Cancer

Pembrolizumab vs. Chemotherapy: Cost-Effectiveness in Lung Cancer

October 28, 2025
blank
Cancer

Intraoperative Targeted Radiation Significantly Lowers Pancreatic Cancer Recurrence Rates

October 28, 2025
Next Post
Transplanted pine seedlings in Interior Alaska

June research news from the Ecological Society of America

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27573 shares
    Share 11026 Tweet 6891
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    982 shares
    Share 393 Tweet 246
  • Bee body mass, pathogens and local climate influence heat tolerance

    649 shares
    Share 260 Tweet 162
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    517 shares
    Share 207 Tweet 129
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    486 shares
    Share 194 Tweet 122
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • 4th Japan-India Universities Forum Convened on 15 November: Advancing Scientific Collaboration
  • Static Magnetic Fields Boost Doxorubicin’s Leukemia Attack
  • STXBP6 Controls Ovarian Cancer via PI3K/AKT Pathway
  • Assessing Turkish Regret Intensity Scale’s Validity and Reliability

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.

Join 5,189 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine